ARKG vs XLV
ARK Genomic Revolution ETF vs Health Care Select Sector SPDR Fund
- • XLV has the lower expense ratio at 0.08% vs 0.75% for ARKG.
- • XLV pays a higher dividend yield (1.38%).
Side-by-side metrics
| Metric | ARKG | XLV |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.75% | 0.08% |
Dividend yield Trailing 12-month yield. | 0.00% | 1.38% |
AUM Assets under management — bigger funds are typically more liquid. | $2.21B | $49.10B |
YTD return | 66.55% | 23.16% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 2.11 | 0.41 |
P/E ratio | — | 30.63 |
Last price | $47.17 | $187.94 |
Inception | — | — |
Issuer | ARK | State Street |
ARKG top holdings
| TWST | Twist Bioscience Corp | 8.75% |
| TXG | 10x Genomics Inc Ordinary Shares - Class A | 8.73% |
| TEM | Tempus AI Inc Class A common stock | 8.36% |
| ABSI | Absci Corp | 5.56% |
| CRSP | CRISPR Therapeutics AG | 5.22% |
| GH | Guardant Health Inc | 4.88% |
| NTRA | Natera Inc | 4.71% |
| ILMN | Illumina Inc | 4.69% |
| LLY | Eli Lilly and Co | 3.92% |
| BEAM | Beam Therapeutics Inc | 3.69% |
XLV top holdings
| LLY | Eli Lilly and Co | 16.88% |
| JNJ | Johnson & Johnson | 9.80% |
| ABBV | AbbVie Inc | 7.76% |
| MRK | Merck & Co Inc | 5.49% |
| UNH | UnitedHealth Group Inc | 5.44% |
| TMO | Thermo Fisher Scientific Inc | 3.84% |
| AMGN | Amgen Inc | 3.75% |
| GILD | Gilead Sciences Inc | 3.15% |
| ABT | Abbott Laboratories | 2.74% |
| PFE | Pfizer Inc | 2.59% |
About ARKG
ARKG (ARK Genomic Revolution ETF) is Companies advancing genomics and molecular biology. Managed by ARK, the fund carries $2.2B in assets under management, an expense ratio of 0.75%. Its largest holding is Twist Bioscience Corp (TWST), which represents 8.7% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.
About XLV
XLV (Health Care Select Sector SPDR Fund) is S&P 500 health care sector. Managed by State Street, the fund carries $49.1B in assets under management, an expense ratio of 0.08%, a dividend yield of 1.38%. Its largest holding is Eli Lilly and Co (LLY), which represents 16.9% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.